# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Natera (NASDAQ:NTRA) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.71) by 21....
Expanded EBLIS study with up to 12 years of clinical follow-up across all subtypes of breast cancer
-Bloomberg
Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomesNat...